16 May 2017
IXICO plc
("IXICO" or the "Company")
Notice of Interim Results
IXICO, the brain health company, will announce its interim results for the six months ended 31 March 2017 on Monday 22 May 2017.
For further information please contact:
IXICO plc Susan Lowther, Chief Financial Officer |
Tel: +44 20 3763 7499 |
Shore Capital (Nomad and Broker) Bidhi Bhoma / Edward Mansfield |
Tel: +44 20 7408 4090 |
|
|
FTI Consulting Limited (Investor Relations) Simon Conway/Mo Noonan |
Tel: +44 20 3727 1000 |
About IXICO
Our mission is to transform the pursuit of improving brain health through the application of digital technologies to neuroscience. IXICO's specialist data analytics services are used by the global Pharmaceutical industry to select patients for clinical trials, assess the safety and efficacy of new drugs in development and in post marketing surveillance. Our neurological disease focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis and Parkinson's and our integrated digital platform encompasses the entire drug development lifecycle. It is a scalable and secure infrastructure for the capture and analysis of regulatory compliant patient clinical data to enable sponsors to make rapid, better informed decisions.
IXICO is also collaborating with partners to develop new companion digital health products targeted at improving patient outcomes
More information is available on www.ixico.com
